Millendo Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Ann Arbor MI United States (2011)
Status: Acquired by Tempest Therapeutics (2021)

Organization Overview

First Clinical Trial
2013
NCT01898715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Millendo Therapeutics, Inc. | Millendo Therapeutics SAS

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Millendo Therapeutics, Inc. (0) Acquired (1)

azp-531 (2 trials)

Drugs in Phase 2 Trials (3)

atr-101 (3 trials)

azd-2624 (1 trial)

nevanimibe hydrochloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Gland Neoplasms (Phase 1)

Adrenal Hyperplasia, Congenital (Phase 2)

Adrenocortical Carcinoma (Phase 1)

Adrenocortical Hyperfunction (Phase 2)

Adrenogenital Syndrome (Phase 2)

Carcinoma (Phase 1)

Cushing Syndrome (Phase 2)

Hyperphagia (Phase 3)

Hyperplasia (Phase 2)

Polycystic Ovary Syndrome (Phase 2)

Prader-Willi Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4